A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants | MicrobiomeTrials← Back to trialsNCT06904261
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-01-08Est. Completion: 2027-12
Enrollment target: 8 participants Locations- Emory Genetics, Atlanta, Georgia, United States
- University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota, United States
- Atrium Health Levine Children's Hospital, Charlotte, North Carolina, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
- Lysosomal and Rare Disorders Research and Treatment Center, Inc., Fairfax, Virginia, United States
- Universitair Ziekenhuis (UZ) Leuven, Leuven, Vlaams-Brabant, Belgium
- Universitäetsklinikum Müenster (UKM) Klinik für Kinder- und Jugendmedizin - Allgemeine Paediatrie, Münster, North Rhine-Westphalia, Germany
- Kitasato University Hospital, Sagamihara, Kanagawa, Japan
- Hospital Universitario de la Paz, Madrid, Madrid, Spain
- Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom
- Manchester University NHS Foundation Trust, Manchester, United Kingdom
Other microbiome trials you might be interested in
Fabry Disease
The aim of this randomized controlled study is to evaluate the effects of a six-week low-fermentable oligosaccharides, d…
Istanbul, Turkey (Türkiye)Est. completion Jan 30, 2027
SplenomegalySplenectomyThrombopeniaInterstitial Lung Disease (ILD)Hypocholesterolemia
The goal of this clinical trial is to optimise and facilitate screening for Acid SphingoMyelinase Deficiency (ASMD) dise…
Paris, FranceEst. completion Mar 1, 2029